Thomas Ciulla MD PC

[ad_1] Our recent paper was “Editor’s Choice”: This post hoc analysis compared #suprachoroidal triamcinolone acetonide (CLS-TA) to other treatments for macular edema due to #uveitis. https://t.co/iFbR8A7DG4 [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @Ophthalmologymg: @BauschLomb’s Xipere therapy offers hope to patients with macular edema associated with non-infectious uveitis. By Kar… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Just presented “The Suprachoroidal Space and Suprachoroidal Delivery for Clinicians” at #Angiogenesis2022, covering key features of #suprachoroidal delivery: targeting & compartmentalization, drivers of durability & posterior flow, therapies in development #eye #retina https://t.co/WYLuN9eb4B [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @RetinaToday: The push for longer-acting therapeutics has garnered us several long-duration corticosteroid therapies to choose from. Thi… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ThomasCiullaMD: Honored to be recognized as a global expert in #maculardegeneration , a leading cause of irreversible vision loss: http… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @RetinaGlobal1: Gene therapy, specifically designed to neutralize #VEGF activity, may be the next approach to the treatment of #diabetic… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Pleased to have led an ARVO Advance Expert Session: The Association for Research in Vision and Ophthalmology- https://t.co/nLybntb8pU https://t.co/5kElblGUAD [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.